The telomeric copy of the survival motor neuron gene (SMN1) is deleted or mutated in all spinal muscular atrophy (SMA) patients and these patients present mainly a loss in spinal motoneurons. Although studies performed in HeLa cells suggest that SMN may be involved in the biogenesis and possibly in recycling of spliceosomal small nuclear ribonucleoproteins (snRNPs), no link has been established between this function and the consequence of the absence of SMN in the specific loss of motoneurons. We attempted to answer the question of whether SMN plays a direct role in motoneuron survival by transducing cultured motoneurons with lentiviral vectors coding either for an antisense Smn mRNA or for full-length or truncated forms of SMN. We studied their effect on survival under different anti-or proapoptotic culture conditions. Our results show that increased levels of SMN are unable to protect motoneurons from death induced by trophic deprivation or by excitotoxicity. These results suggest that SMN is not a survival factor per se for motoneurons. In addition, overexpression of a truncated form of SMN shown to induce a modified subcellular localization and to exert a dominant-negative effect on snRNP biogenesis and RNA splicing in HeLa cells was ineffective in modifying both localization and survival in motoneurons.
INTRODUCTION
Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by the degeneration of spinal cord and brainstem motoneurons (Crawford and Pardo, 1996) and can be divided into three clinical types (types I, II, III) depending on the age of onset and on clinical course. In 1995, J. Melki's group identified the survival motor neuron (SMN) gene located in a 500-kb duplicated region of chromosome 5q13 (Lefebvre et al., 1995) . The telomeric copy of SMN (SMN1) is deleted or mutated in 100% of SMA patients, irrespective of clinical severity, and is therefore considered to be the SMA-determining gene (Lefebvre et al., 1995 (Lefebvre et al., , 1998 . While SMN1 produces mainly full-length protein, the centromeric copy, SMN2, unaffected in SMA patients, undergoes mainly an alternative splicing of exon 7, thus resulting in a putative shorter protein with a different C-terminus sequence (Gennarelli et al., 1995; Lefebvre et al., 1995) . Immunoblot studies on protein extracts of spinal cord or muscle have shown that the amount of SMN protein is decreased in SMA patients with a direct correlation with the clinical severity (Coovert et al., 1997; Lefebvre et al., 1997; Burlet et al., 1998) , suggesting an inverse relation between the level of SMN and the degree of motoneuron loss.
Mice and rats have only one Smn gene for which only a full-length protein is expected since no alternative splicing has been demonstrated in rodents (Bergin et al., 1997; DiDonato et al., 1997; Viollet et al., 1997; Battaglia et al., 1997; La Bella et al., 1998) .
The expression and distribution of SMN have been studied in different cells and tissues (Lefebvre et al., 
